1 in 5 adults may carry a cholesterol particle standard blood tests don't measure

The standard adult cholesterol test is built around LDL, the so-called "bad" cholesterol. That structural choice is why roughly one in five adults carry a genetically determined, LDL-like particle called lipoprotein(a), or Lp(a), that the test does not measure.

A new pooled analysis of more than 20,000 patients, presented at the SCAI 2026 Scientific Sessions, links elevated Lp(a) to higher rates of heart attack, stroke, and cardiovascular death even when LDL looks controlled on standard therapy.

Lp(a) is not a typo for LDL. It is a distinct particle, similar in shape to LDL but with an extra protein, apolipoprotein(a), bolted on. Largely set by their genes rather than by diet or exercise, Lp(a) tends to run in families and stay flat through middle age. Most people never learn their number because the standard lipid panel, the routine cholesterol test ordered at most annual physicals, assays LDL, HDL, and triglycerides, and not Lp(a). A separate, one-time blood test is required, and most clinicians do not order it by default.

The new analysis drew on stored plasma from 20,070 participants aged 40 and older across three long-running NIH-funded randomized trials — ACCORD (type 2 diabetes), PEACE (stable coronary disease), and SPRINT (hypertension). Researchers ran Lp(a) measurements through a single translational lab using a standardized assay, then tracked outcomes in the trial records. High Lp(a) tracked with a higher rate of major cardiovascular events, especially stroke and cardiovascular death, even among participants already on statins, blood pressure control, and other guideline-directed therapy.

Earlier work had tied high Lp(a) to cardiovascular events. The new analysis adds quantitative weight to a more specific question: how much risk survives when LDL, blood pressure, and glucose are already controlled.

The practical implication is not a new drug. No Lp(a)-specific therapy is approved today. A high Lp(a) result changes management by sharpening the case for tighter control of everything that is treatable: lower LDL targets, stricter blood pressure, glucose management, smoking cessation. Current guidelines recommend Lp(a) testing in people with a family history of early heart disease or premature stroke, and in people whose cardiovascular risk does not line up with their LDL numbers, not as a universal screen.

The findings have not yet been published in a peer-reviewed journal. The three source trials enrolled specific populations: type 2 diabetes, stable coronary disease, and hypertension, so a residual-risk signal in their stored samples is hypothesis-strengthening for a general adult population, not a stand-alone practice change. The next move is the peer-reviewed publication and any movement by guideline bodies on whether to expand Lp(a) screening beyond targeted use.